Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC (IMPACT31)
IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Joann Peters, MHA
- Telefonnummer: 434-825-2551
- E-post: peters@geneostx.com
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Har ikke rekruttert ennå
- Emory University
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 404-251-1278
- E-post: kathleen.marie.coleman@emory.edu
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70112
- Rekruttering
- Louisiana State University Health Sciences Center
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 504-568-4750
- E-post: omoave@lsuhsc.edu
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Rekruttering
- Johns Hopkins University
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 410-955-8893
- E-post: GIClinicalTrials@jh.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Har ikke rekruttert ennå
- University of Michigan
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 734-936-8643
- E-post: ndparikh@med.umich.edu
-
-
New York
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 212-241-7840
- E-post: denise.rodriguez3@mssm.edu
-
New York, New York, Forente stater, 10027
- Har ikke rekruttert ennå
- New York Presbyterian Hospital-Columbia University Irving Medical Center
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 212-342-5162
- E-post: Cancerclinicaltrials@cumc.columbia.edu
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Har ikke rekruttert ennå
- MD Anderson Cancer Center
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 713-792-2828
- E-post: GIClinicalTrials@mdanderson.org
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Har ikke rekruttert ennå
- Fred Hutchinson Cancer Center
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 206-667-1392
- E-post: giresearch@fredhutch.org
-
-
-
-
-
Auckland, New Zealand, 1023
- Rekruttering
- Auckland City Hospital (Te Toka Tumai)
-
Ta kontakt med:
- Principal Investigator, MD
- Telefonnummer: 22932 64 0800 488 434
- E-post: LiverResearchUnit@adhb.govt.nz
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Written informed consent
- ≥18 years of age
- Histologically or cytologically confirmed diagnosis of HCC (not accepted: fibrolamellar, sarcomatoid, mixed cholangiocarcinoma)
- Child-Pugh Class A liver score
- Documented virology status of hepatitis
- Availability of a representative post-resection tumor tissue sample
- ECOG performance status of 0 or 1
- Adequate organ function
- Women of childbearing potential (WOCBP) and men must be willing to use an adequate method of contraception
Exclusion Criteria:
- Is currently participating in and receiving study drug or has participated in a study of an investigational agent and received study drug or used an investigation device, within 4 weeks to baseline
- Evidence of residual, recurrent, or metastatic disease at randomization
- Active or history of autoimmune disease or immune deficiency
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Diagnosed additional malignancy within 5 years prior to baseline, except for: (a) non-invasive carcinomas subject to successful curative treatment in the opinion of the investigator which require no further therapy and (b) other malignancies for which subjects have undergone potentially curative therapy and have been considered disease free for at least 3 years prior to screening.
- Active infection requiring systemic therapy
- Is pregnant, breastfeeding or expecting to conceive or father children within the study's projected duration
- History of human immunodeficiency virus (HIV) (HIV I/II antibodies).
- Co-infection with HBV and hepatitis D viral infection
- Co-infection with HBV and HCV
- Has received a live vaccine within 30 days of planned start of study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Personalized Immunotherapy for Cancer:
GNOS-PV02 + INO-9012 ID followed by electroporation every 3 weeks for 4 doses, then every 9 weeks (Q9W) until week 104, then every 12 weeks (Q12W) until week 260 followed by 3 years follow-up survival |
delivered by intradermal injection and electroporation GNOS-PV02 + INO-9012 ID followed by electroporation cytokine interleukin-12 (IL-12), a vaccine adjuvant |
|
Ingen inngripen: Standard of Care
Active Surveillance for 5 years or until recurrence, plus 3 years follow-up survival. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Recurrence-free survival
Tidsramme: Up to 5 years
|
RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first. |
Up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of treatment emergent adverse events (safety and tolerability)
Tidsramme: Up to 5 years
|
Summary adverse events according to CTCAE 6.0 |
Up to 5 years
|
|
Time to extra-hepatic spread or macro-vascular invasion
Tidsramme: Up to 5 years
|
Time to extra-hepatic spread or macro-vascular invasion (TTEHS/MVI) |
Up to 5 years
|
|
Overall survival
Tidsramme: Up to 5 years on study + 3 years follow up
|
OS is defined as time from randomization to death of any cause |
Up to 5 years on study + 3 years follow up
|
|
RFS rate at 12, 18 and 24 months as assessed by the investigator
Tidsramme: Randomization up to 12 months, 18 and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 and 24 months
|
|
RFS rate at 12, 18 and 24 months as assessed by the BIRC
Tidsramme: Randomization up to 12 months, 18 months and 24 months
|
The proportion of patients who remain free from disease recurrence after treatment over a specified period |
Randomization up to 12 months, 18 months and 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- GT-31
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
At the time of registration, the sponsor has not yet determined whether de-identified individual participant data collected during the study will be shared. A decision regarding data sharing will be made following study completion and in accordance with sponsor policies, applicable regulations, and ethical considerations.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .